Bibliography
- Trulock EP, Christie JD, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant 2007;26:782-95
- Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002;21:297-310
- Sharples LD, Mcneil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant 2002;21:271-81
- Burton CM, Iversen M, Scheike T, et al. Is lymphocytic bronchiolitis a marker of acute rejection? An analysis of 2,697 transbronchial biopsies after lung transplantation. J Heart Lung Transplant 2008;27:1128-34
- Kroshus TJ, Kshettry VR, Savik K, et al. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997;114:195-202
- Botha P, Archer L, Anderson RL, et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 2008;85:771-4
- D'ovidio F, Mura M, Tsang M, et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J Thorac Cardiovasc Surg 2005;129:1144-52
- Stovold R, Forrest IA, Corris PA, et al. Pepsin, a biomarker of gastric aspiration in lung allografts: a putative association with rejection. Am J Respir Crit Care Med 2007;175:1298-303
- Babu AN, Murakawa T, Thurman JM, et al. Microvascular destruction identifies murine allografts that cannot be rescued from airway fibrosis. J Clin Invest 2007;117:3774-85
- Valentine VG, Bonvillain RW, Gupta MR, et al. Infections in lung allograft recipients: ganciclovir era. J Heart Lung Transplant 2008;27:528-35
- Chmiel C, Speich R, Hofer M, et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 2008;46:831-9
- Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006;6:3008-16
- Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 2001;33:1397-405
- Ailawadi G, Smith PW, Oka T, et al. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation. J Thorac Cardiovasc Surg 2008;135:594-602
- Hartwig MG, Snyder LD, Appel JZ, et al. Rabbit anti-thymocyte globulin induction therapy does not prolong survival after lung transplantation. J Heart Lung Transplant 2008;27:547-53
- McCurry KR, Iacono A, Zeevi A, et al. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. J Thorac Cardiovasc Surg 2005;130:528-37
- Snell GI, Westall GP. Immunosuppression for lung transplantation: evidence to date. Drugs 2007;67:1531-9
- Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725-38
- Gottlieb J, Szangolies J, Koehnlein T, et al. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008;85:36-41
- Iacono AT, Corcoran TE, Griffith BP, et al. Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans. Eur Respir J 2004;23:384-90
- Label for Nebcin® (Tobramycin for Injection, USP)
- Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30
- Alothman GA, Alsaadi MM, Ho BL, et al. Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. Chest 2002;122:930-4
- Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004;1:338-44
- Abdulhamid I, Wise TL, Andrews S, et al. Elevated serum tobramycin concentrations after treatment with tobramycin inhalation in a preterm infant. Pharmacotherapy 2008;28:939-44
- Laporta R, Ussetti P, Carreno MC. Renal toxicity due to inhaled tobramycin in lung transplant recipients. J Heart Lung Transplant 2006;25:608
- Ahya VN, Doyle AM, Mendez JD, et al. Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient. J Heart Lung Transplant 2005;24:932-5
- Heyder J, Gebhardt J, Rudolf, G. et al. Deposition of Particles in the Human Respiratory Tract in the Size Range of 0.005-15 micron. J Aerosol Science 1986;17:811-25
- Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc 2004;1:315-20
- Chua HL, Collis GG, Newbury AM, et al. The influence of age on aerosol deposition in children with cystic fibrosis. Eur Respir J 1994;7:2185-91
- Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med 2005;172:1497-504
- Laube BL, Jashnani R, Dalby RN, Zeitlin PL. Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate. Chest 2000;118:1069-76
- Svartengren M, Philipson K, Camner P. Individual differences in regional deposition of 6-micron particles in humans with induced bronchoconstriction. Exp Lung Res 1989;15:139-49
- Brown JS, Zeman KL, Bennett WD. Regional deposition of coarse particles and ventilation distribution in healthy subjects and patients with cystic fibrosis. J Aerosol Med 2001;14:443-54
- Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis 1987;136:1445-9
- Smaldone GC, Fuhrer J, Steigbigel RT, McPeck M. Factors determining pulmonary deposition of aerosolized pentamidine in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1991;143:727-37
- Diot P, Palmer LB, Smaldone A, et al. RhDNase I aerosol deposition and related factors in cystic fibrosis. Am J Respir Crit Care Med 1997;156:1662-8
- Mukhopadhyay S, Staddon GE, Eastman C, et al. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir Med 1994;88:203-11
- Condos R, Hull FP, Schluger NW, et al. Regional deposition of aerosolized interferon-gamma in pulmonary tuberculosis. Chest 2004;125:2146-55
- Burns KE, Orons PD, Dauber JH, et al. Endobronchial metallic stent placement for airway complications after lung transplantation: longitudinal results. Ann Thorac Surg 2002;74:1934-41
- Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007;26:1229-42
- Weibel ER. Morphometry of the human lung. Berlin, Springer; 1963
- Corcoran TE, Smaldone GC, Dauber JH, et al. Preservation of post-transplant lung function with aerosol cyclosporin. Eur Respir J 2004;23:378-83
- Corcoran TE, Venkataramanan R, Mihelc KM, et al. Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. Am J Transplant 2006;6:2765-73
- Mitruka SN, Won A, Mccurry KR, et al. In the lung aerosol cyclosporine provides a regional concentration advantage over intramuscular cyclosporine. J Heart Lung Transplant 2000;19:969-75
- Mitruka SN, Pham SM, Zeevi A, et al. Aerosol cyclosporine prevents acute allograft rejection in experimental lung transplantation. J Thorac Cardiovasc Surg 1998;115:28-36; discussion 36-27
- Zenati M, Duncan AJ, Burckart GJ, et al. Immunosuppression with aerosolized cyclosporine for prevention of lung rejection in a rat model. Eur J Cardiothorac Surg 1991;5:266-71; discussion 272
- Wang T, Noonberg S, Steigerwalt R, et al. Preclinical safety evaluation of inhaled cyclosporine in propylene glycol. J Aerosol Med 2007;20:417-28
- Corcoran TE. Inhaled delivery of aerosolized cyclosporine. Adv Drug Deliv Rev 2006
- Iacono AT, Johnson BA, Grgurich WF, et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med 2006;354:141-50
- Iacono AT, Keenan RJ, Duncan SR, et al. Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am J Respir Crit Care Med 1996;153:1451-5
- Gilbert BE, Knight C, Alvarez FG, et al. Tolerance of volunteers to cyclosporine A-dilauroylphosphatidylcholine liposome aerosol. Am J Respir Crit Care Med 1997;156:1789-93
- Zijlstra GS, Rijkeboer M, Jan van Drooge D, et al. Characterization of a cyclosporine solid dispersion for inhalation. Aaps J 2007;9:E190-199
- O'riordan TG, Iacono A, Keenan RJ, et al. Delivery and distribution of aerosolized cyclosporine in lung allograft recipients. Am J Respir Crit Care Med 1995;151:516-21
- Coates AL, Green M, Leung K, et al. The challenges of quantitative measurement of lung deposition using 99mTc-DTPA from delivery systems with very different delivery times. J Aerosol Med 2007;20:320-30
- Burckart G, Smaldone GC, Eldon M, et al. Lung Deposition and Pharmacokinetics of Cyclosporine after Aerosolization in Lung Transplant Patients. Pharm Res 2003;20:252-6
- Knoop C, Vervier I, Thiry P, et al. Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions. Transplantation 2003;76:683-8
- Iacono AT, Smaldone GC, Keenan RJ, et al. Dose-related reversal of acute lung rejection by aerosolized cyclosporine. Am J Respir Crit Care Med 1997;155:1690-8
- Keenan RJ, Iacono A, Dauber JH, et al. Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J Thorac Cardiovasc Surg 1997;113:335-40; discussion 340-331
- Iacono A, Dauber J, Keenan R, et al. Interleukin 6 and interferon-gamma gene expression in lung transplant recipients with refractory acute cellular rejection: implications for monitoring and inhibition by treatment with aerosolized cyclosporine. Transplantation 1997;64:263-9
- Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003;22:258-66
- Martino R. Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature. Curr Med Res Opin 2004;20:485-504
- Olson JA, Adler-moore JP, Jensen GM, et al. Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products. Antimicrob Agents Chemother 2008;52:259-68
- Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 2001;20:1274-81
- Drew RH, Dodds Ashley E, Benjamin DK Jr, et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004;77:232-7
- Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 2003;75:1571-4
- Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001;72:545-8
- Lowry CM, Marty FM, Vargas SO, et al. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study. Transpl Infect Dis 2007;9:121-5
- Shah SP, Misra A. Development of liposomal amphotericin B dry powder inhaler formulation. Drug Deliv 2004;11:247-53
- Westney GE, Kesten S, De Hoyos A, et al. Aspergillus infection in single and double lung transplant recipients. Transplantation 1996;61:915-9
- Saha G. Fundamentals of Nuclear Pharmacy, Fifth Addition: Springer; 2004
- Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003;41:3623-6
- Bayat S, Louchahi K, Verdiere B, et al. Comparison of 99mTc-DTPA and urea for measuring cefepime concentrations in epithelial lining fluid. Eur Respir J 2004;24:150-6
- Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-6
- Diot P, Gagnadoux F, Martin C, et al. Nebulization and anti-Pseudomonas aeruginosa activity of colistin. Eur Respir J 1997;10:1995-8
- Stead RJ, Hodson ME, Batten JC. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest 1987;81:272-9
- Nicholson. Development and Studies of Nebulized SLIT Amikacin for the Treatment of Pseudomonas Aeruginosa Airway Infection in CF (S12.3 Session Summary). Pediatr Pulmonol 2005;40:144
- McCoy KS, Quittner AL, Oermann CM, et al. Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis. Am J Respir Crit Care Med 2008;178:921-8
- Available from: http://www.cff.org/treatments/Pipeline/
- Ward C, De Soyza A, Fisher AJ, et al. Reticular basement membrane thickening in airways of lung transplant recipients is not affected by inhaled corticosteroids. Clin Exp Allergy 2004;34:1905-9
- Whitford H, Walters EH, Levvey B, et al. Addition of inhaled corticosteroids to systemic immunosuppression after lung transplantation: a double-blind, placebo-controlled trial. Transplantation 2002;73:1793-9
- Zheng L, Walters EH, Wang N, et al. Effect of inhaled fluticasone propionate on BAL TGF-beta(1) and bFGF concentrations in clinically stable lung transplant recipients. J Heart Lung Transplant 2004;23:446-55
- De Soyza A, Fisher AJ, Small T, Corris PA. Inhaled corticosteroids and the treatment of lymphocytic bronchiolitis following lung transplantation. Am J Respir Crit Care Med 2001;164:1209-12
- Laube BL, Karmazyn YJ, Orens JB, Mogayzel PJ. Albuterol improves impaired mucociliary clearance after lung transplantation. J Heart Lung Transplant 2007;26:138-44
- Available from: www.optn.org
- Kim IK, Phrampus E, Venkataraman S, et al. Helium/oxygen-driven albuterol nebulization in the treatment of children with moderate to severe asthma exacerbations: a randomized, controlled trial. Pediatrics 2005;116:1127-33
- Papamoschou D. Theoretical validation of the respiratory benefits of helium-oxygen mixtures. Respir Physiol 1995;99:183-90
- Piva JP, Menna Barreto, SS Zelmanovitz, et al. Heliox versus oxygen for nebulized aerosol therapy in children with lower airway obstruction. Pediatr Crit Care Med 2002;3:6-10
- Marcinkowski AL, Garoff S, Tilton RD, et al. Post-deposition dispersion of aerosol medications using surfactant carriers. J Aerosol Med and Pulm Drug Del 2008;21
- Studer SM, George MP, Zhu X, et al. CD28 Downregulation on CD4 T-Cells is a Marker for Graft Dysfunction in Lung Transplant Recipients. Am J Respir Crit Care Med 2008
- Golocheikine AS, Saini D, Ramachandran S, et al. Soluble CD30 levels as a diagnostic marker for bronchiolitis obliterans syndrome following human lung transplantation. Transpl Immunol 2008;18:260-3
- Gast KK, Biedermann A, Herweling A, et al. Oxygen-sensitive 3He-MRI in bronchiolitis obliterans after lung transplantation. Eur Radiol 2008;18:530-7
- Van Muylem A, Knoop C, Estenne M. Early detection of chronic pulmonary allograft dysfunction by exhaled biomarkers. Am J Respir Crit Care Med 2007;175:731-6